The site(s) of action of a bovine pituitary diabetogenic peptide that produces hyperglycemia and hyperinsulinemia in vivo (dogs or humans) was investigated in vitro. When rat diaphragms were incubated with the peptide in the presence of insulin, the peptide depressed insulin-mediated (a) glucose uptake, (b) glycogen synthesis, and (c) glycogen synthase activation (conversion of D to I form). Incubation with the peptide alone resulted in small increases in (a), (b), and (c). Insulin-mediated glycogen synthase kinase inactivation was inhibited when both insulin and peptide were present (d), whereas glycogen synthase kinase activity was lowered by the peptide alone. High doses of insulin completely reversed inhibitory effects of the peptide on glycogen synthesis. Therefore, the hyperglycemic and anti-insulin properties of this peptide in vivo can possibly be explained by the partial blocking action of the peptide on insulin-mediated glucose uptake and glycogenesis.
In 1963, Louis et al. (1) first reported the isolation of a polypeptide exhibiting diabetogenic and anti-insulin properties from urine of human lipoatrophic diabetics. This peptide was not found in the urine of normal subjects. A similar peptide was subsequently isolated from urine of proteinuric diabetic patients without lipoatrophy (2) , as well as from adenohypophyses of beef (3), sheep, pigs (4) , and humans (5) . All peptides produce hyperglycemia and resistance to exogenous insulin when injected into dogs and humans. After purification to homogeneity, all exhibit similar physicochemical and biological properties (5) .
The evidence that the pituitary peptide is not growth hormone or a fragment is: first, that it has no growth-promoting activity (6) ; second, no fragment of growth hormone with diabetogenic activity was isolated when growth hormone was subjected to the same isolation and purification procedures as the peptide (7); and third, there was little or no immunological crossreactivity between growth hormone antiserum and the peptide (5, 8) . Evidence also suggests that this peptide is not adrenocorticotrophic hormone (3) or prolactin (4) . Therefore, the suggestion has been made that this is a novel pituitary peptide (7) .
Since the biological effects of the peptide in vivo suggested an action antagonistic to insulin, we decided to examine this question directly in vitro. We have investigated the mechanism of action in terms of the well established stimulation by insulin of glucose uptake, glycogen synthesis, and the two enzyme perturbations that regulate the latter biochemical action. In the present paper we demonstrate that in addition to blocking each of these four actions of insulin in isolated rat diaphragm, the peptide alone acts as a weak positive effector 2774 on these same four parameters, suggesting that it may act very early in the sequence of actions initiated by insulin.
METHODS AND MATERIALS
Male Wistar rats (140-180 g) were decapitated and their diaphragms were dissected either with or without the rib cage. The diaphragms were placed in plastic beakers containing Krebs-Ringer bicarbonate buffer (20 ml) oxygenated with 02-CO2 95:5 in a metabolic shaker at 37°. After 30 min of incubation, diaphragms were transferred to a second set of beakers containing the same buffer, together with additions as indicated and 5 mM glucose. The diaphragms were incubated for an additional 15 min; the experiment was terminated by rapidly freezing the tissue in liquid nitrogen. Tissues were stored at -70°until analyzed (1-2 days). Aliquots of the medium were removed before and after the final 15-min incubation and frozen for subsequent analysis.
In experiments involving diaphragms attached to rib cages, the diaphragm muscle was removed by chipping in liquid nitrogen. The frozen tissue was powdered in a percussion mortar.
For analysis of [14C]glucose uptake (15-min experimental period), 0.5-ml aliquots of the incubation medium were deproteinized with matched solutions of zinc sulfate and barium hydroxide, shaken with anion-and cation-exchange resins to remove ionic [14C]metabolites, and counted as described by Exton and Park (9) .
['4C]Glycogen was determined on about 100 mg of frozen tissue that was digested at 1000 in 30% KOH. The glycogen was precipitated with 66% ethanol in the presence of 0.4% Na2SO4 at 90°. After centrifugation, the glycogen pellet was dissolved in 0.5 ml of H20 and aliquots were pipetted onto filter papers that were washed, dried, and counted by the procedure of Thomas et al. (10) .
Glycogen Values are expressed as mean i standard error of the mean. Values in parentheses indicate numbers of diaphragms for each mean. The significance of differences between means was established by Student's "t" test. RESULTS Insulin, when added to an isolated rat diaphragm, stimulates glucose uptake and glycogen synthesis (12) , and also produces an increase in the glucose-6-phosphate independent (I) form of glycogen synthase (13) . To establish a relationship between insulin concentration and stimulation of glucose uptake, glycogen synthesis, and glycogen synthase activation, cut rat diaphragms were incubated for 30 min in substrate-free buffer, then transferred to buffer containing 5 mM [14C] The molecular weight for the peptide was 26,000 and for insulin was 6000, so that the peptide to insulin molar ratio was about 2 to 1 for series 1 and 5 to 1 for series 2. 
1-4 glucose (8800 cpm/,smol) with concentrations of insulin from 0 to 10 mU/ml for 15 min of further incubation.
All concentrations of insulin studied ( Fig. 1 ) produced a significant increase in glucose uptake over controls, with no apparent plateau in-the effect of the highest dose studied.
In these same diaphragms, insulin-mediated glycogen deposition ranged from a 27% increase at 0.1 mU/ml to a 380% increase at 10.0 mU/ml (Fig. 2) , again with no apparent plateau.
When the effect of insulin on glycogen synthase activation (shift from D to I form) was studied in the same diaphragms, it was observed that 0.1 mU/ml of insulin produced essentially no increase in synthase activity, whereas 1.0 and 10.0 mU/ml produced 23% and 32% increases, respectively (Fig. 3) .
Thus, 1.0 mU/ml insulin was taken as the lowest effective concentration stimulating glucose uptake, glycogen synthesis, and glycogen synthase activation in isolated cut rat diaphragms under this set of conditions.
When the pituitary peptide was not present in the initial 0-to 30-min incubation period, we observed no inhibition of the effect of insulin on synthase activation (Table 1, P is less than 0.01 for insulin as compared to insulin + peptide.
for 30 min in the presence of an appropriate concentration of the peptide, which was also present during the subsequent 15-min incubation period. Under these conditions, the diabetogenic peptide caused a 30% inhibition of insulin-mediated glucose uptake (Fig. 4) . The insulin concentration in this experiment was 1.0 mU/ml (0.04 ig/ml or 7 nM) and the concentration of diabetogenic peptide was 2 ,ug/ml, constituting a peptide to insulin molar ratio of 10 to 1, similar to that used in vivo (7). The peptide, when present alone, was a weak positive effector significantly augmenting glucose uptake. Under these same conditions, insulin-stimulated glycogen depositionwas inhibited about 23% by the peptide (Fig. 5) . The weak stimulatory effect of the peptide alone was also manifest on glycogen synthesis.
The effects of insulin and of the diabetogenic peptide on glycogen synthase activation (Table 2) were then evaluated on 4 and 5. 0.04 jug/ml of insulin = 1 mU/ml; 0.2 Ag/ml of insulin = 5 mU/ml. * P is less than 0.01 as compared to control. t P is less than 0.01 as compared to control, and P is less than 0.05 as compared to insulin + peptide. The effect of insulin, as well as the insulin-like effect of the peptide alone, are significant in series 1. Furthermore, the trend towards inhibition of insulin-mediated synthase activation by the peptide is present, although it is not statistically significant. Since the effect of insulin on synthase activation was small, and basal synthase activity was high in cut diaphragms, additional experiments were performed with a higher concentration of insulin and the more stable intact diaphragm preparation in order to obtain a larger synthase activation and lower basal activity.* These experiments (series 2) demonstrate that the peptide inhibits insulin-mediated synthase activation and, in addition, that the peptide by itself has an insulin-like effect. In order to investigate further the site of action of the peptide, glycogen synthase kinase activity was determined in Sephadex-treated extracts from diaphragms incubated under the same conditions as series 2 of Table 2 . The results are shown in Table 3 . In agreement with findings first reported by Villar-Palasi and Wenger (15) , and later confirmed by Shen et al. (11) , insulin produced a decrease in the cyclic AMPindependent form of synthase kinase from 57 to 17%. With insulin plus the peptide, the insulin-mediated shift in kinase activity was completely inhibited and was indistinguishable from the effect of the peptide. The peptide alone caused a significant insulin-like shift in kinase activity. Thus, the effects of the peptide on the kinase could explain the effects of the peptide on glycogen synthase activation and on glycogen synthesis.
Inhibition of insulin-mediated glycogenesis by the diabetogenic peptide was a reversible process (Table 4 ). The effects of 1 and 5.0 mU/ml of insulin were inhibited by 2.0 Ag/ml of the peptide, while the same peptide concentration had no effect in the presence of 50.0 and 500.0 mU/mi of insulin. * Higher % of I form levels of synthase activity in cut as compared to intact diaphragm preparations were probably dt:e to enhanced glycogenolysis associated with cut muscle fibers. The inverse relationship between glycogen levels and % of I synthase is well established (14) .
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DISCUSSION
We were attracted to the bovine pituitary peptide as a potential insulin antagonist because of our interest in the mechanism of insulin action to effect glycogen synthase activation (shift from D to I form) and synthase kinase inactivation (shift from I to D form). In the present paper, we have presented evidence that the peptide, when incubated with rat diaphragm, partially blocks the four actions of insulin studied, including the kinase shift. This report thus represents an independent confirmation of the synthase kinase perturbation by insulin (11, 15) . Molar ratios of peptide to insulin approach those used in vivo, adding further significance to these results. Furthermore, the initial 30-min incubation with the peptide required to achieve these blocking effects does not appear inordinately stringent compared to the long-term (4-24 hr) injection schedules used in vivo.t It would appear from the present experiments that antagonism to the action of insulin peripherally could possibly explain the anti-insulin, as well as the hyperinsulinemic, effects observed in vivo.
At least two other important points emerge from these experiments. First, the insulin-like action of the peptide alone and the insulin antagonistic action on two experimentally separable insulin-sensitive processes, namely glucose uptake and the glycogenic cascade (16) , suggest that the peptide may act very early in the insulin-mediated mechanism. This suggestion is further borne out by the complete reversal of the blocking action by higher insulin dosages. Second, the partial blocking of these four events, including the synthase kinase shift, provides a parameter that has been singularly absent in studies of insulin action up to this point, namely, reversal by a blocking agent. The importance of such a tool is so well established in the case of adrenergic cholinergic and other classic pharmacologic systems that it provides one portion of the definition of the receptor. It is possible to suggest that the 
